US regulatory easing to boost South Korean biosimilar firms

The United States Congress is poised to reform regulations governing the biosimilar market, a move anticipated to significantly benefit South Korean biotechnology firms. Proposed legislative changes aim to lower the barriers to entry for biosimilar drugs and curb the misuse of patent protections by original drug manufacturers.

These reforms are expected to create a more favorable environment for biosimilar companies seeking to compete in the lucrative US market. By streamlining approval processes and addressing patent-related challenges, the legislation could accelerate the availability of more affordable biologic medicines.

South Korean companies, particularly Celltrion and Samsung Bioepis, are positioned to be major beneficiaries of these regulatory shifts. Both firms have already established a presence and expanded their market share in the US. The anticipated easing of regulations is likely to further bolster their growth and solidify their leading positions in the global biosimilar landscape.